Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.82 |
| ▸ | NT5E | P21589 | 1/20 | 0.77 |
| ▸ | KRAS | P01116 | 5/20 | 0.74 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.73 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.67 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.66 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.66 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17072523 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL80058 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL37405 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL101367 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18775378 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL23969756 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| Triphosphate SCHEMBL28597197 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18785111 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144860-A1 | FLUORESCENT GTP ANALOGUES AND USE | CISBIO BIOASSAYS (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-8557844-B2 | Substrate reduction therapy | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8557844-B2 | Substrate reduction therapy | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | disclosed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2009001097-A2 | SUBSTRATE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008012555-A2 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | TGM2 3027/4885NT5E 2746/4885KRAS 3753/4885 |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | TGM2 787/4885NT5E 2161/4885KRAS 2484/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | TGM2 787/4885NT5E 2161/4885KRAS 2484/4885 |
| US-20220144860-A1 | FLUORESCENT GTP ANALOGUES AND USE | GNAI3, GNAQ, GNB1 | TGM2 140/4885NT5E 344/4885KRAS 9/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | TGM2 382/4885NT5E 2276/4885KRAS 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.